[
    {
        "utterance": "Matt Bogyo: some intros just so we all know again about what people do. Uh just as a reminder what my background is uh chemistry and specifically um synthesis of mainly optical based probes. We do a little bit of pet and now some ultrasound as well. Um but mainly yeah trying to develop agents that can report on specific biological signatures namely proteolytic signatures is what we do a lot of. Um not we don't do that much metabolite stuff but we we are starting to get interested more in lipid metabolites as well. Um so I I think it's easiest if I just call out people looking around the top of my screen here so maybe start with Molly. I know you're eating sorry. ",
        "annotations": {
            "explain or define term or concept": "The speaker is explaining his background and the type of research his lab does, specifically defining the agents they develop and the biological signatures they target.",
            "encourage particpatioin": "The speaker is inviting Molly to introduce herself and her work, encouraging her participation in the introductions."
        }
    },
    {
        "utterance": "Jin Zhang: Sorry, sorry. ",
        "annotations": {
            "acknowledge contribution": "Jin Zhang acknowledges Matt Bogyo's prior statement and introduction."
        }
    },
    {
        "utterance": "Matt Bogyo: Okay, let's go to Kevin. Let's let's go to Kevin. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is encouraging Kevin to participate by calling on him to speak."
        }
    },
    {
        "utterance": "Jin Zhang: Matt, can I um intervene? Sorry, before everything, um can we uh identify a reporter um uh recorder/reporter from this group? If you have done the job uh previously, you you don't have to do it or uh and um anyone else can we have a volunteer? ",
        "annotations": {
            "ask clarifying question": "Jin asks if they can intervene, likely to bring up a point before the introductions continue.",
            "propose decision": "Jin proposes the decision to identify a recorder/reporter for the group, suggesting they find a volunteer.",
            "encourage particpatioin": "Jin encourages participation by asking for a volunteer to be the recorder/reporter."
        }
    },
    {
        "utterance": "Kevin Cash: Sure, I can do it. ",
        "annotations": {
            "confirm decision": "Kevin agrees to Jin's request to be the recorder/reporter for the group."
        }
    },
    {
        "utterance": "Jin Zhang: Great. Thanks, Kevin. And um do you want to uh set up a Google Doc? Would that is is that possible? And then we can sort of do the notes there and then copy and paste. ",
        "annotations": {
            "express agreement": "Jin Zhang expresses agreement with Kevin's offer to be the recorder.",
            "propose decision": "Jin Zhang proposes setting up a Google Doc for note-taking during the meeting."
        }
    },
    {
        "utterance": "Kevin Cash: Sure, I can do that. ",
        "annotations": {
            "confirm decision": "Kevin agrees to Jin's request to set up a Google Doc for notes, finalizing the decision."
        }
    },
    {
        "utterance": "Jin Zhang: Okay, great. And um if you can share that link and other people can also um add uh additional comments notes to that doc. Uh sorry Matt for introduce the introduction. We probably want to have the reporter sort it out. ",
        "annotations": {
            "express agreement": "Jin Zhang expresses agreement with Kevin's offer to be the reporter.",
            "assign task": "Jin Zhang assigns Kevin the task of sharing the Google Doc link and allowing others to add comments.",
            "acknowledge contribution": "Jin Zhang apologizes to Matt for interrupting the introductions, acknowledging his contribution."
        }
    },
    {
        "utterance": "Matt Bogyo: No, you can. ",
        "annotations": {
            "express agreement": "Matt Bogyo expresses agreement with Jin Zhang's intervention to identify a reporter for the meeting."
        }
    },
    {
        "utterance": "Jin Zhang: And also I wonder if we want to take one minute to write down some thoughts uh about this topic and then because quite often when the intro starts, um you know that naturally go into the the discussion. ",
        "annotations": {
            "propose decision": "Jin Zhang suggests taking a minute to write down thoughts about the topic, proposing a concrete action for the group to take before the discussion begins."
        }
    },
    {
        "utterance": "Matt Bogyo: Sure, yeah, you can do it that way. That's fine. ",
        "annotations": {
            "express agreement": "Matt Bogyo agrees with Jin Zhang's suggestion to take a minute to write down thoughts about the topic before starting introductions, indicating agreement with the proposed approach."
        }
    },
    {
        "utterance": "Jin Zhang: Right, sorry. I promise after this I'll let you take over. Okay, maybe we take one minute to write down actually for you know uh past a few sessions we didn't have to go to these notes but just in case um we take you know maybe one minute to write down some thoughts about this topic. Again, um it's about metabolites uh I think there are some suggested topics um can uh metabolic imaging be used diagnostically uh mass spec imaging is leading the way um but can that be used together with other imaging methodologies. ",
        "annotations": {
            "propose decision": {
                "Explanation": "The speaker suggests taking one minute to write down thoughts about the topic, proposing a concrete action for the group."
            },
            "explain or define term or concept": {
                "Explanation": "The speaker explains that the topic is about metabolites and mentions suggested topics like metabolic imaging being used diagnostically, providing context for the discussion."
            }
        }
    },
    {
        "utterance": "Jin Zhang: Can aptamers and other probes be developed for this? Uh those are the three um topics uh you know sort of initially posed. Posted. Um so okay, one minute start now. ",
        "annotations": [
            {
                "present new idea": "The speaker is introducing the idea of developing aptamers and other probes for the topic at hand, which hasn't been explicitly mentioned before.",
                "propose decision": "The speaker is proposing the group to start a one-minute period to write down thoughts about the topic."
            }
        ]
    },
    {
        "utterance": "Jin Zhang: All right, I think that's it. Um feel free to refer to that these notes um or um if there's a pause maybe Matt or I will ask you to read from your notes. Uh so Matt, you can take over for the intro now. ",
        "annotations": {
            "assign task": "Jin Zhang assigns Matt the task of taking over the introduction, as she had been managing the initial logistics.",
            "encourage particpatioin": "Jin Zhang encourages participation by saying that if there is a pause, Matt or she will ask the participants to read from their notes."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, sure. Um Molly's done eating so we can go back to Molly. ",
        "annotations": {
            "acknowledge contribution": "Matt acknowledges that Molly is done eating, which allows them to proceed with the introductions as previously planned."
        }
    },
    {
        "utterance": "Molly Bright: I know. Coffee's coming. Um yeah, I'm Molly Bright. I'm at Northwestern in Chicago. ",
        "annotations": [
            {
                "None": "This sentence does not fit any of the codes in the codebook."
            },
            {
                "None": "This sentence does not fit any of the codes in the codebook."
            },
            {
                "None": "This sentence does not fit any of the codes in the codebook."
            }
        ]
    },
    {
        "utterance": "Molly Bright: Okay. ",
        "annotations": {
            "None": "This utterance does not contain any content that can be categorized by the codebook."
        }
    },
    {
        "utterance": "Kevin Cash: Kevin Cash from Colorado School of Mines and my lab makes nanoparticle based sensors and one of our key applications is measuring oxygen dynamics in a range of microbial and in vivo systems as a proxy for metabolism. ",
        "annotations": {
            "explain or define term or concept": "Kevin explains that his lab uses nanoparticle-based sensors to measure oxygen dynamics as a proxy for metabolism, clarifying their application."
        }
    },
    {
        "utterance": "Kevin Cash: So rather than measuring a wide suite of things, we measure oxygen and say, well, that's a good proxy for what's going on and use that to look at spatial and temporal dynamics. ",
        "annotations": {
            "explain or define term or concept": "Kevin explains that measuring oxygen dynamics serves as a proxy for metabolism, clarifying their approach to understanding biological processes.",
            "expand on existing idea": "Kevin expands on his lab's work with nanoparticle-based sensors, detailing their application in measuring oxygen dynamics as a proxy for metabolism in microbial and in vivo systems."
        }
    },
    {
        "utterance": "Matt Bogyo: Okay, great. ",
        "annotations": {
            "express agreement": "Matt Bogyo expresses agreement with Kevin Cash's introduction of his work on nanoparticle-based sensors for measuring oxygen dynamics as a proxy for metabolism."
        }
    },
    {
        "utterance": "Matt Bogyo: How about uh Sue? Sue, I guess. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is inviting Sue to introduce herself and her work, similar to how he asked Molly and Kevin to speak earlier in the conversation."
        }
    },
    {
        "utterance": "Seu Sim: Hello. So I'm an assistant professor in chemistry at UC Irvine and I'm a soft matter chemist, meaning I engineer polymers and proteins with living cells. So I'm currently interested in organizing bacterial communities within three dimensional mesh or 3D printed architectures and understand their dynamics and interactions. ",
        "annotations": {
            "explain or define term or concept": "The speaker explains that she is a soft matter chemist, defining it as engineering polymers and proteins with living cells."
        }
    },
    {
        "utterance": "Seu Sim: Nice to meet you all. ",
        "annotations": {
            "express enthusiasm": "Seu Sim expresses enthusiasm by saying \"Nice to meet you all\" at the end of their introduction."
        }
    },
    {
        "utterance": "Matt Bogyo: Okay uh Candace. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is calling on Candace to introduce herself and her work, encouraging her participation in the introductions."
        }
    },
    {
        "utterance": "Candace Fleischer: Hi, I'm Candace Fleischer at Emory. Uh my lab primarily does in vivo MR spectroscopy and thermometry of the human brain. ",
        "annotations": {
            "None": "This utterance is a self-introduction, providing background information about the speaker and their lab's research focus, but it does not fit into any of the defined codes."
        }
    },
    {
        "utterance": "Matt Bogyo: Uh Alex. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is calling on Alex to introduce themself and their work, continuing the round of introductions."
        }
    },
    {
        "utterance": "Walsh, Alex: Hi, I'm Alex. I'm at Texas A&M University and I do optical imaging of mostly fluorescence and fluorescence lifetime of NADH and FAD. So those are molecules used in metabolic processes. So we're um able to to image something about metabolism that way. ",
        "annotations": {
            "explain or define term or concept": "The speaker explains that NADH and FAD are molecules used in metabolic processes, providing context for their imaging work."
        }
    },
    {
        "utterance": "Matt Bogyo: Uh Allison. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is calling on Allison to introduce herself and her work, encouraging her participation in the introductions."
        }
    },
    {
        "utterance": "Allison Dennis: Hi, I'm Allison Dennis. I'm at Boston University. I um work on fluorescence sensors and fluorescent imaging contrast agents and one of the things that projects that seems most relevant to this uh discussion is we have some small molecule fret sensors that use allosteric transcription factors to bind and unbind DNA in response to a small molecule being around. So if there were favorite transcription factors for metabolites that would be something we'd be interested in making sensors for for example. ",
        "annotations": {
            "present new idea": "Allison introduces the idea of using small molecule FRET sensors that use allosteric transcription factors to bind and unbind DNA in response to a small molecule, which is a novel concept in the context of the discussion so far.",
            "expand on existing idea": "Allison expands on the idea of fluorescence sensors and fluorescent imaging contrast agents, which she works on, by mentioning a specific project involving small molecule FRET sensors.",
            "provide supporting evidence": "Allison provides supporting evidence for the relevance of her work by mentioning that they have small molecule fret sensors that use allosteric transcription factors, which could be relevant to the discussion on metabolites.",
            "explain or define term or concept": "Allison implicitly explains the concept of FRET sensors in the context of her work, clarifying how they function with allosteric transcription factors and DNA binding in response to small molecules.",
            "express enthusiasm": "Allison expresses enthusiasm by stating that they would be interested in making sensors for favorite transcription factors for metabolites, indicating a positive interest in the topic."
        }
    },
    {
        "utterance": "Allison Dennis: Thanks. ",
        "annotations": {
            "None": "This utterance does not contain any content that fits the codebook."
        }
    },
    {
        "utterance": "Matt Bogyo: All right, great. Ping. ",
        "annotations": {
            "express agreement": "Matt Bogyo says \"All right, great\" which expresses agreement with the previous speaker.",
            "encourage particpatioin": "Matt Bogyo says \"Ping\" to encourage Ping to participate in the discussion."
        }
    },
    {
        "utterance": "Ping Wang: Hi, um I'm Ping Wang, um assistant professor in radiology from uh Michigan State. Um I I was trained as interventional radiologist and uh develop uh interest in molecular imaging um of diabetes. Uh so the research work in my lab uh mainly focus on uh using imaging uh matters to track the transplanted uh human islet uh and also the stem cell differentiate islet organoids. Um we also uh work a little bit on the nano drug delivery to the targeting the endogenous beta cells. Uh the imaging modality uh we uh use often uh include uh MRI, uh pet MRI um and uh we use the optical imaging um system all the time. Um now uh we have been studying using um magnetic particle imaging. Uh looking forward to have the um discussions with all of you. ",
        "annotations": {
            "explain or define term or concept": "The speaker explains their background and research focus, including molecular imaging of diabetes, tracking transplanted human islets, stem cell differentiation, nano drug delivery, and imaging modalities like MRI, PET/MRI, and optical imaging.",
            "present new idea": "The speaker introduces their work on magnetic particle imaging, which is a novel concept not previously mentioned by others in the introductions."
        }
    },
    {
        "utterance": "Matt Bogyo: Great, Catherine. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is inviting Catherine to introduce herself and her work, continuing the round of introductions."
        }
    },
    {
        "utterance": "Katharine White: Hi, I'm Katherine White. I'm an assistant professor at the University of Notre Dame and my lab sits at the interface between chemical biology and and cancer cell biology. We develop new optogenetic tools that allow us to manipulate intracellular pH in single cells in real time. Um and as it relates to the kind of concepts here, we're interested in understanding how pH dynamics affect proteins, pathways, cell behaviors and we have some really interesting data uh linking initial pH changes with with metabolic reprogramming that we would like to better understand the dynamics of of that cross talk. So ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker is introducing their lab's focus on optogenetic tools and their application to manipulating intracellular pH, which serves to explain their area of expertise to the group."
            },
            {
                "present new idea": "The speaker introduces the idea of linking initial pH changes with metabolic reprogramming, which is a novel concept not previously mentioned by others."
            }
        ]
    },
    {
        "utterance": "Katharine White: Great. ",
        "annotations": {
            "express agreement": "Katharine White expresses agreement with the previous turn, indicated by her saying \"Great.\""
        }
    },
    {
        "utterance": "Matt Bogyo: Thanks uh Lou. ",
        "annotations": {
            "acknowledge contribution": "Matt Bogyo acknowledges the previous speaker's introduction by saying thanks."
        }
    },
    {
        "utterance": "Lu Wei: Hi, I'm Lou. Um um I'm assistant professor of chemistry at Caltech. Um so we work on um broadly vibrational uh spectroscopy and and microscopy uh mostly currently on on stimulate Raman. ",
        "annotations": {
            "explain or define term or concept": "Lu Wei mentions \"vibrational spectroscopy and microscopy\" and \"stimulate Raman\", which could be unfamiliar to some participants, thus explaining the terms for clarity.",
            "present new idea": "Lu Wei introduces their work on vibrational spectroscopy and microscopy, specifically stimulate Raman, which is a new area of expertise not previously mentioned by others."
        }
    },
    {
        "utterance": "Lu Wei: Um so we are actually trying to push Rama into a um uh well Raman guided uh spatial metabolomics platform. Um so on a single cell level we're trying to um connect the dots, uh draw the correlation between Rama measurements on both spectroscopy and imaging side to uh single ",
        "annotations": {
            "present new idea": "Lu Wei introduces the novel concept of pushing Raman spectroscopy into a Raman-guided spatial metabolomics platform, which hasn't been mentioned before.",
            "explain or define term or concept": "Lu Wei explains that they are trying to connect the dots and draw correlations between Raman measurements on both spectroscopy and imaging side to single cells, clarifying the goal of their platform."
        }
    },
    {
        "utterance": "Lu Wei_Caltech: cell transcriptomics, um, uh, and also the mass spec, uh, measurement on the on the bulk level. Um, on the, uh, specially resolved level, we're trying to identify new signatures from Raman and trying to, um, resolve the metabolic control, um, um, um, for disease systems. So, uh, recently we, uh, we're trying to identify, um, the metabolic system abilities during, uh, the development of drug resistance in, uh, melanoma patients. ",
        "annotations": {
            "expand on existing idea": "Lu Wei is building upon their introduction of Raman spectroscopy and microscopy by adding details about connecting it to single-cell transcriptomics and mass spec measurements.",
            "explain or define term or concept": "Lu Wei is explaining the concept of Raman-guided spatial metabolomics platform and how it is used to identify new signatures from Raman to resolve metabolic control.",
            "provide supporting evidence": "Lu Wei provides the example of identifying metabolic system abilities during the development of drug resistance in melanoma patients as a specific application of their work."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Great. Uh, Lingyan. ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is inviting Lingyan to introduce herself and her work, continuing the round of introductions."
        }
    },
    {
        "utterance": "Lingyan Shi: Hi, um, my name is Lingyan Shi. I'm an assistant professor in UCSD at the bioengineering department. Our my lab is developing optical imaging techniques such as SRS and multifoton fluorescence microscopy. So we have been integrating two imaging modalities together to visualize the metabolic activities in living living organisms. So there are two layers of of imaging approach. One is the label free including the fluorescence multifoton fluorescence for example, we look at the NADH or flavor molecules in the living organism. And another layer is the Raman label free approach that we can visualize those lipids and protein information inside the animals and tissues. And we also want to separate the new molecules, uh newly synthesized molecule from the older endogenous molecules. So we have been also label those metabolites such as using heavy water or deterium labeled glucose amino acids to probe the metabolic activities in the live animals. So uh in that case we can separate those new molecules from the older molecules and uh quantitatively image the metabolic turnover rate for each of the macro molecules in the in the body. And uh very glad to discuss with you all today. Thank you. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker explains their lab's work in developing optical imaging techniques like SRS and multifoton fluorescence microscopy, clarifying their approach to visualizing metabolic activities.",
                "present new idea": "The speaker introduces the idea of separating newly synthesized molecules from older endogenous molecules using labeled metabolites to probe metabolic activities, which is a novel approach not previously discussed in the introductions.",
                "express enthusiasm": "The speaker expresses enthusiasm by stating they are very glad to discuss with everyone today, showing excitement for the collaboration."
            }
        ]
    },
    {
        "utterance": "Matt Bogyo - Stanford: Great. That's a good group. I think we have a lot of people working on metabolites, also tons of different modalities and different approaches to imaging, which so it should be a good discussion. Um, I mean, I guess to kick it off, we could start with the sort of first prompt, which I thought was kind of interesting is the idea of metabolites being a sort of early stage, um, reporter for bigger biological processes. So can they be used for diagnostic purposes and um, maybe that would be a good place to start if people have some ideas about that topic. ",
        "annotations": {
            "express enthusiasm": "Matt expresses enthusiasm about the group and the potential for a good discussion, given the diverse expertise in metabolites and imaging modalities.",
            "propose decision": "Matt proposes to start the discussion with the first prompt, which is about using metabolites as early-stage reporters for diagnostic purposes, suggesting it as a good starting point.",
            "present new idea": "Matt introduces the idea of metabolites being early stage reporters for bigger biological processes, which is the first prompt for discussion."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: And I might broaden it out a bit to rather than just like measuring the metabolic things directly, do patterns in it change, do um, variability in measurements change, like what other things can we use that might be diagnostically relevant before we see physiological impacts. ",
        "annotations": {
            "expand on existing idea": "Kevin builds on Matt's idea of using metabolites for diagnostic purposes by suggesting to broaden the scope to include patterns and variability in metabolic measurements, not just direct measurements.",
            "present new idea": "Kevin introduces the idea of using patterns and variability in metabolic measurements as diagnostically relevant factors before physiological impacts are observed."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, that actually sort of uh um is related to uh one of the uh things that mentioned by different people. I think in terms of looking at metabolites uh or metabolic processes uh what I guess what are the targets, the variety of different targets that we're we're thinking about. I I guess uh summarizing different, you know, different people's uh intro, uh, you know, we looked at uh newly synthesized metabolites as a sort of a whole class, uh specific species, um, NADPH, NADH, uh or oxygen uh as a proxy or or uh developing specific probes for a very specific metabolite. So uh there these are all possibilities. What are some of the advantages uh and challenges uh of targeting these different things for looking at metabolites and metabolic processes. And as Kevin mentioned, uh perhaps, you know, patterns, uh features of any of those, right? as a you know, class uh or as a individual species could be used for diagnostic purpose. Just to uh throw the question out there. ",
        "annotations": {
            "expand on existing idea": "Jin Zhang builds upon Matt's initial prompt about using metabolites for diagnostic purposes by relating it to the targets people are considering when looking at metabolites and metabolic processes.",
            "ask clarifying question": "Jin Zhang asks about the advantages and challenges of targeting different metabolites and metabolic processes, expanding on Kevin's idea of looking at patterns and variability in metabolic measurements for diagnostic relevance.",
            "present new idea": "Jin Zhang presents the idea of using patterns or features of metabolites, either as a class or individual species, for diagnostic purposes, building on the discussion about metabolites as early-stage reporters for biological processes."
        }
    },
    {
        "utterance": "Katharine White - Notre Dame: I can talk about if um, yeah. ",
        "annotations": {
            "encourage particpatioin": "Katharine is offering to speak, which encourages further discussion and participation from others."
        }
    },
    {
        "utterance": "Lingyan Shi: May I may I say something about the newly synthesized one with labeling? ",
        "annotations": {
            "encourage particpatioin": "Lingyan Shi is asking for permission to speak and contribute to the discussion about newly synthesized metabolites with labeling, which encourages participation from others."
        }
    },
    {
        "utterance": "Lingyan Shi: to break the diffraction limit limitation to have a better spatial resolution. ",
        "annotations": {
            "expand on existing idea": "Lingyan Shi is expanding on the previous discussion about metabolites and metabolic processes by suggesting a method to improve spatial resolution, building upon the ongoing conversation about different targets and their advantages."
        }
    },
    {
        "utterance": "Katharine White: Yeah, I just wanted to if I can add on onto that because I think you brought up a lot of really interesting points there. Uh, one of which is this kind of spatial resolution of metabolism and so, you know, a lot of the approaches that we have on the cell biology side in terms of, you know, broad population level metabolomics are not sufficient for a lot of the questions that apparently everyone in this group is is similarly thinking about in terms of the spatial organization in 3D and in a tissue where oxygen gradients, pH gradients, nutrient availability might be very altered and so this this ability to get it at spatial organization of metabolism within a cell, within tissue, within an organism I think is is really important and we need to think about the the needs there and then um, you know, I I think it's fascinating that you want subpixel um information there. That is just blows my mind because we can't even get, you know, reasonable dynamic measurements in a single cell sometimes and so the idea that you could have that kind of of uh resolution is is really interesting to me. ",
        "annotations": [
            {
                "expand on existing idea": "Katharine builds upon the previous discussion about metabolites and metabolic processes, adding the point about the importance of spatial resolution of metabolism, which was brought up by multiple people."
            },
            {
                "provide supporting evidence": "Katharine supports the need for better spatial resolution by stating that current broad population level metabolomics approaches are insufficient for addressing questions about spatial organization in 3D tissues with varying oxygen, pH, and nutrient gradients."
            },
            {
                "acknowledge contribution": "Katharine acknowledges Lingyan Shi's contribution regarding subpixel information, expressing amazement at the possibility of achieving such high resolution."
            }
        ]
    },
    {
        "utterance": "Katharine White: Um, but I think coming this connects also to to Kevin's point about heterogeneity and uh at the, you know, uh what is the variability that we're interested in and and what is the sensitivity that we need in our measurement tool to be uh confident that we're capturing that variability if it's biologically meaningful. ",
        "annotations": {
            "expand on existing idea": "This utterance builds upon Kevin's earlier point about heterogeneity in metabolic measurements, adding the consideration of variability and sensitivity needed in measurement tools to capture biologically meaningful variations.",
            "provide supporting evidence": "The speaker is providing reasoning to strengthen the idea of considering heterogeneity by highlighting the importance of variability and sensitivity in measurement tools to ensure the captured variability is biologically meaningful.",
            "ask clarifying question": "The speaker is asking what variability we are interested in and what sensitivity we need in our measurement tool."
        }
    },
    {
        "utterance": "Katharine White: And as as we come at this problem, we see a lot of these correlations at the population level that we're not able to confirm at a single cell level reliably. And so one of the uh questions that maybe we can kind of jump off of where Kevin uh and Lingyan got us started is, you know, what are the constraints there? What is the what is the need in terms of probes in terms of to make these kind of leaps from maps or measurements to diagnosis to phenotype to um outcome. ",
        "annotations": {
            "expand on existing idea": "Building on the discussion about spatial resolution and heterogeneity of metabolism, Katharine expands on the challenges of confirming population-level correlations at the single-cell level, which was previously mentioned by Kevin and Lingyan.",
            "ask clarifying question": "Katharine asks about the constraints and needs in terms of probes to make leaps from measurements to diagnosis, phenotype, and outcome, seeking to clarify the requirements for advancing metabolic research."
        }
    },
    {
        "utterance": "Seu Sim: So I I make polymers. So I something that I wrote down here. I I love the idea of using mass spectrometry to look at the metabolomic processes, but as many of you pointed out, it's a very small scale problem. So we can also imagine using expansion microscopy, but then you have to think of a way to anchor your molecules of interest in a reliable way so that it flies. So have anyone, you know, read anything about it and, you know, any experiences I would love to talk about it. ",
        "annotations": [
            {
                "present new idea": "The speaker introduces the idea of using expansion microscopy to address the small-scale problem of metabolomic processes, which is a novel approach not previously discussed in this specific context.",
                "ask clarifying question": "The speaker asks if anyone has read about or has experience with anchoring molecules of interest for expansion microscopy, seeking information and experiences from the group.",
                "express enthusiasm": "The speaker expresses enthusiasm for the idea of using mass spectrometry to look at metabolomic processes, indicating excitement about this approach."
            }
        ]
    },
    {
        "utterance": "Matt Bogyo: So do do people know currently for like what's I mean, I know mass spec is being used as an imaging technique and that's good for small metabolites, but um obviously it has limitations because you have to process samples in a very specific way. Um yeah, I guess the question is, you know, how do you integrate those technologies into something that's a reasonable diagnostic workflow for for like a clinical specimen or are we talking about samples that would be biopsied or where where do you guys see the application in metabolic profiling? ",
        "annotations": {
            "explain or define term or concept": "The speaker explains that mass spec is being used as an imaging technique and is good for small metabolites, but has limitations because of sample processing requirements.",
            "ask clarifying question": "The speaker asks how to integrate technologies into a reasonable diagnostic workflow for a clinical specimen, or if the discussion is about biopsied samples, seeking clarity on the application of metabolic profiling.",
            "encourage particpatioin": "The speaker asks where others see the application in metabolic profiling, inviting others to contribute their perspectives."
        }
    },
    {
        "utterance": "Lingyan Shi: Well, um yes, I think one application is already uh being conducting in hospital with SRS, the stimulated Raman microscopy is to uh really separate those cancer cell from the normal normal tissue. For example, the the brain tumor case. So for the brain tumor removal, the surgeon will just take take out the just open the skull and take out the brain tumor and they usually will do assess on that uh scar wall inside the brain to to see if there's any tumor cell left inside the brain. So the traditional or conventional way is to just take a little very little tiny piece out and do the histology image H and E staining to to check if the cell uh are all brain cells and there's no tumor cells left inside. So then we can close the skull and wake up the patient. ",
        "annotations": {
            "provide supporting evidence": "Lingyan describes an existing application of SRS in hospitals to differentiate cancer cells from normal tissue during brain tumor removal, providing a real-world example to support the discussion on metabolic profiling.",
            "explain or define term or concept": "Lingyan explains the process of brain tumor removal and the use of SRS (stimulated Raman microscopy) to differentiate cancer cells from normal tissue, clarifying the application of the technology.",
            "expand on existing idea": "Lingyan expands on the discussion of integrating technologies for diagnostic workflows by providing a specific example of SRS being used in hospitals for brain tumor removal, building upon Matt's question about the application of metabolic profiling."
        }
    },
    {
        "utterance": "Lingyan Shi: But usually it takes the conventional method usually takes too long and uh maybe a few hours so that the patient will be under anesthesia for a few hours waiting for the results. But now um since SRS allow us to visualize the protein and the lipids very rapidly. Well for example I I I take like five minutes to take the image when you have that piece of tissue and immediately you have the digital H and E maybe H and E and the pathologist can look at the H image in a few minutes and determine if there's tumor still left or not. So it saves a few hours and uh the patient can be wake up very soon um not they they don't need to be under anesthesia for that long. So it's kind of protecting the brain. Also it's it's a biopsy. It's a it's a diagnostic biopsy um during the clinical clinical clinical period. So I think that types of like fast rapid diagnostic molecular level determination of based on the imaging technology such as SRS may uh be helpful. ",
        "annotations": {
            "provide supporting evidence": "The speaker provides evidence for the utility of SRS by comparing it to the conventional method of tumor detection, highlighting the time saved and reduced anesthesia time for patients.",
            "explain or define term or concept": "The speaker explains the application of SRS in a clinical setting, specifically for distinguishing cancer cells from normal tissue during brain tumor removal.",
            "expand on existing idea": "The speaker expands on the discussion of using imaging technologies for diagnostic purposes by providing a specific example of SRS in brain tumor detection, building on the previous discussion about integrating technologies into a diagnostic workflow."
        }
    },
    {
        "utterance": "Matt Bogyo: So what other types of modalities do you guys think would be useful? Obviously, so Raman is one, right, that we're just talking about. Are are other people here have expertise in other modalities that could be applied in the sort of clinical setting? And maybe also maybe we could think about some of the limitations to that strategy using Raman or ",
        "annotations": [
            {
                "ask clarifying question": "Matt is asking what other modalities besides Raman could be useful in a clinical setting, seeking to broaden the discussion based on the previous discussion about Raman microscopy."
            },
            {
                "encourage particpatioin": "Matt is inviting others to contribute their expertise on different modalities that could be applied in a clinical setting, building on the discussion about Raman microscopy."
            }
        ]
    },
    {
        "utterance": "Ping Wang: I I just want to add a little bit to the discussion. Um, for the um, for the first question, um, metabolic change, uh, I mean, use metabolic imaging used for diagnostically. If you include cancer, um, like I mean, as as a disease for for like a cancer metabolic imaging as part of the discussion, I think it's already been widely used. ",
        "annotations": {
            "expand on existing idea": "Ping Wang wants to add to the discussion about metabolic imaging for diagnostics, which Matt Bogyo initiated, by stating that metabolic imaging is already widely used for cancer diagnosis.",
            "provide supporting evidence": "Ping Wang supports the idea of using metabolic imaging diagnostically by stating that it is already widely used in cancer, providing evidence for its potential application."
        }
    },
    {
        "utterance": "Ping Wang: I mean, it's a clinical modality. I mean, pet I uh especially for pet like FDG uh F18 FDG, that's widely used every day for the diagnosis. Um, and for another disease I have been working on for diabetes, um, yeah, it's it's closely to the glucose metabolism. ",
        "annotations": {
            "provide supporting evidence": "Ping Wang provides evidence that metabolic imaging is already used diagnostically by stating that PET imaging with FDG is widely used for cancer diagnosis, supporting the idea that metabolites can be used for diagnostic purposes, which was brought up by Matt Bogyo and Kevin Cash.",
            "expand on existing idea": "Ping Wang expands on the idea of using metabolic imaging for diagnostics by mentioning its application in diabetes research, building upon the previous discussion about cancer diagnosis using PET imaging."
        }
    },
    {
        "utterance": "Ping Wang: Uh so um in terms of diabetes um there's a there's a very big problem for us like for the endogenous beta cell imaging, beta cell mass imaging. That's a very big problem and people trying to solve this problem for 20 years still not successful. Um because of limited uh special resolution and also the sensitivity we use. We have been tried with the MRI mostly and some people tried pet. So that's why people trying to uh combine the pet MRI uh to complement each other to increase the uh sensitivity and the special resolution. Um in creating um like receptor imaging also it's a big big part for the metabolic imaging. Um example for that is the GLP1 glucagon like peptide one. Um that's also related to the beta cell imaging. ",
        "annotations": {
            "expand on existing idea": "Building on the discussion of metabolic imaging for diagnostics, Ping Wang elaborates on the challenges in diabetes research, specifically endogenous beta cell imaging, which connects to the broader topic of using metabolic imaging for diagnostic purposes.",
            "provide supporting evidence": "Ping Wang supports the claim that endogenous beta cell imaging is a big problem by stating that people have been trying to solve it for 20 years without success, citing limitations in special resolution and sensitivity.",
            "present new idea": "Ping Wang introduces the idea of combining PET and MRI to complement each other and increase sensitivity and special resolution for beta cell imaging, which is a new approach in the context of the discussion.",
            "explain or define term or concept": "Ping Wang explains that receptor imaging, exemplified by GLP1 (glucagon-like peptide 1), is a significant part of metabolic imaging, clarifying a specific application within the broader field."
        }
    },
    {
        "utterance": "Ping Wang: I do have another I do have a question for Kevin. to for for my uh experiment. ",
        "annotations": {
            "ask clarifying question": "Ping Wang is asking a question to Kevin related to their experiment, indicating a need for clarification or further information."
        }
    },
    {
        "utterance": "Ping Wang (MSU): uh the lack of oxygen, um and lack of the blood supply um is may contributors for this um eyelid organoids uh graphs um loss. ",
        "annotations": {
            "provide supporting evidence": "Ping Wang is providing evidence related to the factors contributing to the loss of islet organoid grafts, specifically mentioning the lack of oxygen and blood supply, which supports the discussion on metabolic imaging and its diagnostic applications."
        }
    },
    {
        "utterance": "Ping Wang (MSU): So um if if you can comment on that um like if we can label the cells with some nanoparticles uh you you design synthesize as an indicator uh for the oxygen um I mean level uh in the transplant sites. ",
        "annotations": {
            "ask clarifying question": "Ping Wang is asking Kevin to comment on whether they can label cells with nanoparticles to indicate oxygen levels in transplant sites, building on Kevin's earlier mention of nanoparticle-based sensors for measuring oxygen dynamics."
        }
    },
    {
        "utterance": "Ping Wang (MSU): That's probably uh one I mean application for clinic because you know in clinic for eyelid transplantation for type one diabetes um one recipient usually need two donors, the eyelid from two donors. And uh the clinical data showed nowadays like less than 50% of the recipients um can remain independent uh insulin independence after five years. So ",
        "annotations": {
            "provide supporting evidence": "The speaker provides clinical data showing that less than 50% of islet transplant recipients remain insulin independent after five years, supporting the need for improved monitoring techniques.",
            "expand on existing idea": "The speaker expands on the application of oxygen level indicators in islet transplantation, building on the previous discussion about metabolic imaging for diagnostic purposes and the challenges in beta cell imaging."
        }
    },
    {
        "utterance": "Ping Wang (MSU): we trying to develop something like uh maintain the function of the eyelid uh graphs. ",
        "annotations": {
            "expand on existing idea": "Ping Wang is expanding on the discussion of metabolic imaging for diagnostics, specifically in the context of diabetes and islet transplantation, by mentioning the goal of maintaining the function of islet grafts, which builds upon the previous discussion of challenges in beta cell imaging and islet transplantation."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: I mean at least for our technology in particular, ",
        "annotations": {
            "explain or define term or concept": "Kevin is about to explain or define something specific about their technology, as indicated by the phrase \"for our technology in particular\", which suggests he will provide details or context about it."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: it likely wouldn't work because our stuff's all optical. So if it's actually transplanted into a patient, uh it's not optically accessible anymore. ",
        "annotations": {
            "reject idea": {
                "Explanation": "Kevin rejects Ping's idea of using his nanoparticle-based oxygen sensors for transplanted islet organoids because his technology is optical and wouldn't be accessible in a transplanted patient."
            }
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: But I'm sure there's other oxygen sensitive approaches that would work in that deeper tissue. ",
        "annotations": {
            "expand on existing idea": "This utterance expands on the previous discussion about using oxygen levels as a diagnostic marker, suggesting that alternative oxygen-sensitive approaches could be used in deeper tissues where optical methods are not suitable."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: But just the the ones we do are all optical because for us we're doing most of our stuff either near surface or in in vitro model systems. ",
        "annotations": {
            "explain or define term or concept": "Kevin explains that their oxygen sensing technology is optical, meaning it relies on light, because they primarily work with near-surface or in vitro systems, clarifying the scope of their work."
        }
    },
    {
        "utterance": "Ping Wang (MSU): Yeah, some uh developed for the optical imaging can um also can be considered like radio labeled, yeah, for para paramize. ",
        "annotations": {
            "expand on existing idea": "Ping Wang is expanding on the discussion of optical imaging modalities by suggesting that they can be radiolabeled for paramazation, building on the previous discussion of imaging techniques like Raman and their potential clinical applications."
        }
    },
    {
        "utterance": "Ping Wang (MSU): Okay. ",
        "annotations": {
            "Okay": {
                "Code Name": "acknowledge contribution",
                "Explanation": "Ping Wang is acknowledging Kevin Cash's response to her question about oxygen sensing in transplant sites."
            }
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: So what are some of the, I mean I'm just starting to think do people know I I don't keep up with as much about the metabolism imaging field, but I know like FDG is a big one, right? But that's just that's basically uptake of a reporter molecule by cancer cells. ",
        "annotations": {
            "explain or define term or concept": "Matt Bogyo explains that FDG is basically the uptake of a reporter molecule by cancer cells, clarifying the concept of FDG in metabolic imaging.",
            "provide supporting evidence": "Matt Bogyo mentions FDG as a prominent example in metabolism imaging, supporting the idea that metabolites can be used for diagnostic purposes, as previously discussed.",
            "ask clarifying question": "Matt Bogyo asks about other known examples in the metabolism imaging field, seeking to broaden the discussion beyond FDG."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: But are there other classes of like contrast agents for example that that bind or that are mimics of metabolites and that accumulate much like FDG so that are used in other areas? Seems like that's another area that would be important. ",
        "annotations": {
            "ask clarifying question": "Matt is asking if there are other contrast agents, similar to FDG, that bind or mimic metabolites and accumulate in other areas, seeking to understand the breadth of available tools for metabolic imaging.",
            "expand on existing idea": "Matt is expanding on the discussion about metabolic imaging for diagnostic purposes, specifically building on the example of FDG and inquiring about other similar contrast agents."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah, I can talk briefly about MR spectroscopy, which I'm guessing most of you are familiar with, but it it is a marker of um or it is a method that can measure, you know, quantitative metabolite concentrations localized in whatever region. And it is used in the clinic, cancer is a good example, it's used for um like fatty liver disease. Um, but you do get like basically you get in vivo MR spectra um localized. ",
        "annotations": [
            {
                "explain or define term or concept": "Candace explains MR spectroscopy as a method to measure quantitative metabolite concentrations, providing clarity on the technique in the context of the discussion about metabolic imaging."
            },
            {
                "provide supporting evidence": "Candace mentions that MR spectroscopy is used in the clinic for cancer and fatty liver disease, providing examples of its practical application as a diagnostic tool."
            }
        ]
    },
    {
        "utterance": "Matt Bogyo - Stanford: It's also sampling error, right? I mean because you have to know where you want to look, right? ",
        "annotations": {
            "ask clarifying question": "Matt is asking for confirmation about whether MR spectroscopy has sampling error, given that Candace mentioned it can measure quantitative metabolite concentrations localized in a region."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah, I mean we can do whole brain, you can do multiple regions. I guess um yeah, I mean in a clinical setting you would do a small region of interest. Um so you'd have some information already. Um but I guess in terms of the bigger question of metabolism, you know, um something that is kind of emerging is genetic counseling. So using, you know, gene mutations to predict disease. ",
        "annotations": {
            "expand on existing idea": "Candace is expanding on the previous discussion about MR spectroscopy by mentioning that whole brain or multiple regions can be scanned, addressing Matt's concern about sampling error.",
            "provide supporting evidence": "Candace provides supporting evidence by mentioning that MR spectroscopy is used in the clinic for cancer and fatty liver disease, supporting its clinical applicability.",
            "present new idea": "Candace introduces the idea of genetic counseling as an emerging approach, suggesting using gene mutations to predict disease in relation to metabolism."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): And I guess the idea that I had with metabolic imaging is really, you know, we're not looking at kind of metabolism reprogramming, which we know is really common in cancer, but it's actually probably related to a number of different diseases, diabetes like Ping was saying. And so thinking about the very big picture is, you know, genetics are what we always go to for everything, right? ",
        "annotations": {
            "expand on existing idea": "Candace expands on the idea of metabolic imaging for diagnostics, building on previous discussion about its use in cancer and diabetes.",
            "provide supporting evidence": "Candace mentions that metabolism reprogramming is common in cancer and related to other diseases like diabetes, which Ping mentioned, providing evidence for the broader applicability of metabolic imaging.",
            "present new idea": "Candace introduces the idea of using metabolic imaging to look at metabolism reprogramming in various diseases, contrasting it with the current focus on genetics."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Cancer, do some genetics tests. Um children do some sort of genetic screening, etc, etc. But metabolism is often left out and we know like the prompt is saying, we know that metabolic changes can actually proceed any physiological or structural changes. So from a very big picture, imaging metabolism with maybe in the clinic with the exception of FDG pet and some other tracers from mostly cancer, right? ",
        "annotations": {
            "present new idea": "Candace introduces the idea that metabolic changes can precede physiological or structural changes, suggesting a new perspective on disease diagnosis.",
            "provide supporting evidence": "Candace supports her idea by referencing the prompt, which also suggests that metabolic changes can precede physiological or structural changes.",
            "expand on existing idea": "Candace expands on the idea of genetic counseling by suggesting that metabolism is often left out despite metabolic changes potentially preceding physiological changes, building on the discussion about diagnostic applications of metabolic imaging."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Um is is pretty absent. And so I think there is a big need for thinking about this on a very large scale in terms of, you know, why is metabolism important? Is it important? How is it important? Um and obviously with something like MRI we're working on a very macroscopic scale like you said, we have large regions. ",
        "annotations": {
            "present new idea": "Candace suggests that there is a need for thinking about metabolism on a very large scale, which is a novel concept in the context of the discussion.",
            "explain or define term or concept": "Candace explains that with MRI, they are working on a very macroscopic scale, referring to large regions, which clarifies the limitations of the technology.",
            "provide supporting evidence": "Candace supports her idea by stating that metabolic changes can precede physiological or structural changes, providing a reason why metabolism is important."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): So is MRI done like pretty routinely now like for for metabolic imaging in cancer? ",
        "annotations": {
            "ask clarifying question": "Candace is asking for confirmation on how routinely MRI is used for metabolic imaging in cancer, seeking to clarify its current status."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Like I mean it does it does seem like it requires a lot of time and instrumentation and cost and other things. I mean are there barriers there? ",
        "annotations": {
            "ask clarifying question": "Candace is asking about the barriers to using MRI for metabolic imaging in cancer, specifically mentioning time, instrumentation, and cost, which seeks clarification on the limitations of the method."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Um, I mean it it I would say in many clinics it is done routinely. Um it it depends a little on the tumor, but it's the exact same instrumentation and anytime someone has a tumor you would scan them with an MRI anyway. So they're already in the scanner if you allow if your site does spectroscopy, ",
        "annotations": [
            {
                "provide supporting evidence": "The speaker states that MR spectroscopy is done routinely in many clinics, using the same instrumentation as standard MRI scans for tumors, supporting the feasibility of its use for metabolic imaging."
            }
        ]
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): it's it's naturally integrated into every MRI whether you use it or not. You you kind of have to pay extra for it when you're buying your system. So if you didn't do that you won't have it. But um even non-academic sites are using spectroscopy for tumors. Um so I wouldn't say it's routine, but I would say for so for example for fatty liver disease it is routine because that's a really great way to quickly sample fat distribution. ",
        "annotations": {
            "provide supporting evidence": "Candace provides evidence that MR spectroscopy is integrated into every MRI system, though it may require an extra payment, and that even non-academic sites use spectroscopy for tumors, and it is routine for fatty liver disease.",
            "explain or define term or concept": "Candace explains that MR spectroscopy is a method that can measure quantitative metabolite concentrations localized in a region, building on the discussion of metabolic imaging and its applications.",
            "expand on existing idea": "Candace expands on the idea of using MRI for metabolic imaging by providing details about its integration into MRI systems and its routine use for certain conditions like fatty liver disease, following a discussion about the potential of metabolic imaging for diagnostics."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah. Cool. ",
        "annotations": [
            {
                "express agreement": "Candace agrees with the previous statement about the routine use of MRI for metabolic imaging, indicating agreement with the information provided."
            },
            {
                "express enthusiasm": "Candace expresses enthusiasm with the word \"Cool\", showing a positive reaction to the information about MRI."
            }
        ]
    },
    {
        "utterance": "Lu Wei, Caltech: So following up on that, I actually I'm interested to understand some of the technical challenges across different modalities. ",
        "annotations": {
            "ask clarifying question": "Lu Wei is asking to understand the technical challenges across different modalities, following up on the discussion about metabolic imaging and its applications in clinical settings, specifically MR spectroscopy."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So for example, Candace you just said uh for MRI um to do metabolic imaging, what are the I mean for from a technical point of view, what are the challenges that limits is for the applications? What are the issues you usually run into? ",
        "annotations": {
            "ask clarifying question": "Lu Wei is asking Candace to elaborate on the technical challenges of using MRI for metabolic imaging, following up on Candace's previous statements about MR spectroscopy."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So for example for us, um I I guess for for for FDG for pet in order to overcome those fast decay, you have to prepare the sample very fast and then you only have a limited window to do the imaging. Um for us for Rama, we have the corresponding uh deuterium version of glucose or alcohol version of glucose that we can image. Uh which worked very well at a relatively longer time scale, um but uh with a shorter time scale, for example on the minutes or uh tens of minutes level where I usually limited by uh the sensitivity. So we don't have we don't have enough molecule accumulated for detection. ",
        "annotations": {
            "explain or define term or concept": "The speaker explains the technical challenges of using FDG for PET imaging, specifically the need for rapid sample preparation due to fast decay.",
            "provide supporting evidence": "The speaker provides evidence about the limitations of Raman imaging at shorter time scales due to sensitivity issues, relating it to the accumulation of molecules for detection."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: And also um uh I I saw there's a question on um whether there's a aptamer uh based uh probes that could be developed to imaging metabolites. ",
        "annotations": {
            "expand on existing idea": "This utterance builds upon the previous discussion about imaging metabolites and the potential for developing aptamer-based probes, referencing a question that was previously raised."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Great questions. ",
        "annotations": {
            "express agreement": "Jin Zhang acknowledges Lu Wei's questions as great, expressing agreement with the value or relevance of the questions posed."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): So do we want to start one you know, do one by one? ",
        "annotations": {
            "propose decision": {
                "Explanation": "Jin Zhang proposes a decision to address the questions one by one, suggesting a structured approach to the discussion."
            }
        }
    },
    {
        "utterance": "Lu Wei, Caltech:  ",
        "annotations": [
            {
                "None": "No code applies to this utterance as it is an incomplete sentence."
            }
        ]
    },
    {
        "utterance": "Jin Zhang (UCSD): You Candace, you want to um answer uh uh ",
        "annotations": {
            "encourage particpatioin": "Jin Zhang is encouraging Candace to answer the question about technical challenges in MRI for metabolic imaging that Lu Wei asked, following up on Candace's previous comments about MR spectroscopy."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): the question about the the limitation I guess I I also have related the question whether for the MRI metabolic imaging this is looking at fat, right? And uh and uh are there uh you know, you know, limitations what um uh was asking. but in terms of uh expanding it, you know, is there a need for metabolic profiling for looking at um more uh or or more specific species of metabolites and things along that line. ",
        "annotations": {
            "ask clarifying question": "Jin is asking Candace to clarify if MRI metabolic imaging is limited to looking at fat, building on Lu Wei's question about technical challenges of MRI.",
            "expand on existing idea": "Jin expands on the discussion about limitations of MRI metabolic imaging by asking if there is a need for metabolic profiling to look at more specific metabolites, building on the previous discussion about the use of MRI for metabolic imaging."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): And then I'll come back to the uh buffering problem of a probe based. ",
        "annotations": {
            "expand on existing idea": "This utterance refers back to a previous discussion about the 'buffering problem of a probe based' approach, indicating an intention to elaborate on that specific point later in the conversation."
        }
    },
    {
        "utterance": "Candace Fleischer: um, you know, hydrogen nuclei, which is are present in everything. Um, so I think those are the pros, but it's certainly challenging. And then, you know, on the other side of things, the analysis is difficult. So while there's some inline analysis, so you know, a radiologist can sit at the scanner and see peaks and get approximate idea of patterns. Um, it's not 100% quantitative, it's not standardized across sites. Um, I guess that's those are big medical imaging questions separately even from metabolism is um, are those limitations. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker is explaining that MRI uses hydrogen nuclei, which are present in everything, to measure metabolite concentrations."
            },
            {
                "provide supporting evidence": "The speaker is providing supporting evidence about the challenges of MRI, such as the difficulty of analysis, lack of standardization across sites, and the fact that it's not 100% quantitative, to support the discussion about the limitations of MRI for metabolic imaging."
            }
        ]
    },
    {
        "utterance": "Jin Zhang: Well, I guess related to that, there perhaps um, there isn't a need to really look at very, very specific species, right, in that setting. Just uh looking at overall perhaps, you know, phospho phosphorus um or or fat signal, um you don't have to really look at a one particular lipid species. That's my question related to the MRI. ",
        "annotations": {
            "ask clarifying question": "Jin Zhang is asking whether there is a need to look at very specific species of metabolites in MRI, or if looking at overall signals like phosphorus or fat is sufficient, which is a request for clarification on the limitations and needs of MRI metabolic imaging."
        }
    },
    {
        "utterance": "Candace Fleischer: You don't have to, but I would say most people do. ",
        "annotations": {
            "express agreement": "Candace agrees with the idea that one does not *have* to look at very specific species, but clarifies that most people *do* look at specific species, indicating agreement with the initial statement but adding a nuance."
        }
    },
    {
        "utterance": "Jin Zhang: Sorry. ",
        "annotations": {
            "express agreement": "Jin Zhang is apologizing for interrupting the speaker, Matt Bogyo, and taking over the conversation to organize the meeting logistics, showing agreement with the need to handle the logistics."
        }
    },
    {
        "utterance": "Candace Fleischer: I said you don't have to, but most people do. So, for example, in tumors, um, you know, for Raman biopsy is one example, but we can also do that with MR spectroscopy and see the boundary of the tumor and actually we're using that in our clinic to guide radiation therapy. ",
        "annotations": {
            "expand on existing idea": "Candace expands on the previous discussion about MRI and metabolic imaging by stating that while it's not mandatory to look at specific species, most people do, and provides an example of using MR spectroscopy to see the boundary of a tumor to guide radiation therapy, building upon Jin's question about the need to look at specific species.",
            "provide supporting evidence": "Candace provides supporting evidence by giving an example of how MR spectroscopy is used in their clinic to guide radiation therapy by visualizing the tumor boundary, supporting the idea that specific species are often examined in MRI metabolic imaging."
        }
    },
    {
        "utterance": "Candace Fleischer: Um so we can take an image and see areas that were weren't resected given metabolic ratios in the brain and then we can target those regions. Um, so you you're right, you certainly don't have to. It can be untarget kind of an untarget metabolomics approach. ",
        "annotations": {
            "expand on existing idea": "Candace expands on the previous discussion about MR spectroscopy by explaining how it can be used to guide radiation therapy by identifying areas that were not resected based on metabolic ratios.",
            "express agreement": "Candace agrees with Jin Zhang's statement that it is not necessary to look at very specific species, but clarifies that most people do look at specific species.",
            "explain or define term or concept": "Candace explains that MR spectroscopy can be used as an untargeted metabolomics approach."
        }
    },
    {
        "utterance": "Candace Fleischer: . ",
        "annotations": [
            {
                "None": "No code applies to this utterance."
            }
        ]
    },
    {
        "utterance": "Jin Zhang: So come back coming back to um, Lou's question about the uh uh is it Lou or Way? Sorry. ",
        "annotations": {
            "ask clarifying question": "Jin Zhang is asking for clarification on the correct pronunciation of a name mentioned earlier in the discussion, specifically whether it is 'Lou' or 'Way'."
        }
    },
    {
        "utterance": "Lu Wei: Lou, Lou. ",
        "annotations": {
            "acknowledge contribution": "Lu Wei is correcting Jin Zhang on the pronunciation of their name, which acknowledges Jin Zhang's attempt to address them."
        }
    },
    {
        "utterance": "Lu Wei: Unmuted. It's Lou, yeah. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "The speaker is acknowledging that Jin Zhang was trying to pronounce their name and is confirming the correct pronunciation."
            }
        }
    },
    {
        "utterance": "Jin Zhang: Lou, okay. Lou's question about um the uh um buffering effect. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Jin Zhang acknowledges Lou's prior question about the buffering effect, recognizing Lou's input to the discussion."
            }
        }
    },
    {
        "utterance": "Jin Zhang: Um so this you know, of course uh if we design optical probe or or some of the other probes to to um bind to a specific molecule or uh you know, replace that endogenous molecule with a labeled molecule. Uh there there's uh you know, unwanted effect um uh like a buffering effect uh or or perturbation effect. But I guess the idea is um if you can really enhance the sensitivity and to, you know, to use that as a tracer, right? That's kind of the the pet um imaging that's what the based on, you know, you can really enhance the sensitivity lower the the amount of labeling. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker is explaining the potential unwanted effects, such as buffering or perturbation, that can occur when designing probes to bind to specific molecules or replace endogenous molecules with labeled ones, which is relevant to the discussion about metabolic imaging."
            },
            {
                "expand on existing idea": "The speaker is building on the previous discussion about the limitations of probes and suggesting that enhancing sensitivity and using them as tracers, similar to PET imaging, could mitigate these effects by lowering the amount of labeling needed."
            }
        ]
    },
    {
        "utterance": "Jin Zhang: Then you're uh going to the the sweet spot of um be able to detect something but not perturbing that much. Anyone want to chime in? I think Axon develop probes for uh along this line. Sorry, Sue was going to say something. ",
        "annotations": {
            "expand on existing idea": "This sentence builds on the previous discussion about the buffering effect of probes, suggesting that enhancing sensitivity and lowering labeling can lead to a sweet spot where detection is possible without significant perturbation.",
            "encourage particpatioin": "Jin Zhang encourages others to contribute to the discussion by asking \"Anyone want to chime in?\"",
            "acknowledge contribution": "Jin Zhang acknowledges that Axon develops probes along this line, recognizing their contribution to the field.",
            "express politeness": "Jin Zhang apologizes to Sue for potentially interrupting her, showing consideration for her contribution."
        }
    },
    {
        "utterance": "Seu Sim: Oh, I was actually thinking in this domain. I I like the idea of aptamer based, but I also like the idea of like not just a binding event, something that's amplifiable so that we bring like the low concentration of metabolite into readable range. So in the spirit of lowest possible perturbation and something that's amplifiable, not just, oh, it it's bound to like A bound to B and that's definitely not going to be easy to detect. So I don't know if it's possible, but if we can think of it a way to, you know, bring this aptamer or nucleic acid based binding event and lead that into some amplification event so that we have dynamic range to read out rare metabolite that could be of interest can be an interesting direction. ",
        "annotations": {
            "expand on existing idea": "Seu Sim expands on the idea of aptamer-based probes, which was brought up by Lu Wei and Jin Zhang, by suggesting that the binding event should be amplifiable to bring low concentrations of metabolites into a readable range.",
            "present new idea": "Seu Sim presents a novel concept of combining aptamer-based probes with an amplification event to enhance the detection of rare metabolites, which hasn't been explicitly mentioned before.",
            "offer constructive criticism": "Seu Sim critiques the idea of a simple binding event (A bound to B) for aptamer-based probes, suggesting it might not be sensitive enough and proposing an amplification strategy to improve detection."
        }
    },
    {
        "utterance": "Jin Zhang: Actually kind of contrary to the idea of having the amplification. ",
        "annotations": {
            "reject idea": "Jin Zhang is rejecting the idea of amplification of signal from aptamer binding events, which Seu Sim proposed in the previous utterance."
        }
    },
    {
        "utterance": "Allison Dennis: I go back and forth on whether it's better to have or it's just application dependent, whether it's better to have that one snapshot with the amplification of signal, but then it's an an irreversible signal, right? You're always only increasing never, you know, playing with the the kinetics to have unbinding of the metabolite that you're you're sensing and and bringing the signal back down. So, you know, depending on the the uh dynamics of what the the molecule that you're trying to sense, it could be that you want that accumulation of signal um just to see it at all or you might want a a reversible signal so that you see the the uptick and then the the decline of the reduction in the concentration of that metabolite um in response to something. Just a a totally different design um for the two outcomes. ",
        "annotations": {
            "expand on existing idea": "Allison expands on the idea of amplification of signal, which Seu Sim introduced, by discussing the trade-offs between irreversible amplification and reversible signals depending on the application and the dynamics of the metabolite being sensed.",
            "provide supporting evidence": "Allison supports her point by explaining that an irreversible signal is good for seeing the signal at all, while a reversible signal is good for seeing the uptick and decline of the metabolite concentration."
        }
    },
    {
        "utterance": "Jin Zhang: Yeah, but perhaps for for different applications, uh that could, you know, the the different uh focuses or strategies. But I guess in principle, it is possible to build some amplification not for the binding part of it. ",
        "annotations": {
            "expand on existing idea": "This utterance builds upon the previously discussed idea of amplification strategies for metabolite detection, suggesting that different applications might require different approaches.",
            "express agreement": "The speaker agrees with the previous discussion about different strategies for different applications."
        }
    },
    {
        "utterance": "Jin Zhang: Well, some simple applica amplification that you that's used by people in the field. Of course, there's enzymatic um amplification and um uh and there's transcriptional uh based. I think Andrew put it in the in the chat, ribo switch. ",
        "annotations": {
            "expand on existing idea": "Jin Zhang is expanding on the idea of amplification strategies for metabolite detection, building on Seu Sim and Allison Dennis's discussion about aptamer-based amplification and reversible signals by mentioning enzymatic and transcriptional amplification methods.",
            "provide supporting evidence": "Jin Zhang provides supporting evidence for amplification strategies by mentioning enzymatic and transcriptional amplification, and referencing Andrew's suggestion of riboswitches in the chat."
        }
    },
    {
        "utterance": "Andrew Feig: Yeah, so consider um you might want to look at some of the systems that have been developed by the synthetic biology community, the gem circuits where you can they actually have modular circuits that are integrators for instance and uh that do uh uh timed phase as well. ",
        "annotations": [
            {
                "expand on existing idea": "Andrew is building on the discussion about amplification strategies for metabolite detection by suggesting the use of systems developed by the synthetic biology community, specifically GEM circuits, which were mentioned in the context of transcriptional-based amplification."
            }
        ]
    },
    {
        "utterance": "Andrew Feig: Well, so there there are a whole bunch of these that have been developed with uh different logics on circuits. ",
        "annotations": {
            "expand on existing idea": "Andrew Feig is building upon the discussion of amplification strategies for metabolite detection, referencing systems developed by the synthetic biology community, specifically GEM circuits, which were mentioned in the context of enzymatic and transcriptional amplification."
        }
    },
    {
        "utterance": "Seu Sim: Right. ",
        "annotations": {
            "express agreement": "The speaker is agreeing with the previous discussion about synthetic biology and circuits."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and modular circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim agrees with the previous discussion about synthetic biology and GEM circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is expressing agreement with the previous discussion about synthetic biology and circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and modular circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and GEM circuits for metabolite detection."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous turn, but the specific point of agreement is unclear without more context."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is expressing agreement with the previous discussion, though the specific point of agreement is not clear from this isolated utterance."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim says \"Yeah\", which expresses agreement with the previous turn."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim says \"Yeah\", which expresses agreement with the previous turn."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim simply says \"Yeah\", which expresses agreement with the previous turn."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim says \"Yeah\" in response to Andrew Feig's suggestion to consider systems developed by the synthetic biology community, indicating agreement with the suggestion."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is expressing agreement with the previous discussion, but the specific point of agreement is unclear without more context."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim's utterance of 'Yeah' expresses agreement with the previous discussion about amplification strategies for metabolite detection."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim expresses agreement with the previous discussion about synthetic biology and modular circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about amplification strategies for metabolite detection, as indicated by the repeated 'Yeah'."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is expressing agreement with the previous discussion about amplification strategies for metabolite detection."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is expressing agreement with the previous discussion about amplification strategies for metabolite detection."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about amplification strategies for metabolite detection."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about amplification strategies for metabolite detection."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and modular circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "express agreement": "Seu Sim is agreeing with the previous statement."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and gem circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and gem circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and gem circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": [
            {
                "express agreement": "Seu Sim is agreeing with the previous discussion about synthetic biology and gem circuits."
            }
        ]
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "express agreement": "Seu Sim is agreeing with the previous statement."
        }
    },
    {
        "utterance": "Candace Fleischer: products. ",
        "annotations": [
            {
                "None": "No code applies to this utterance."
            }
        ]
    },
    {
        "utterance": "Jin Zhang: Great. Um, I wonder if Alex or Molly want to chime in for any of the topics, look at your notes. ",
        "annotations": {
            "encourage particpatioin": "Jin Zhang is explicitly inviting Alex and Molly to share their thoughts on the topics discussed, encouraging their participation in the conversation."
        }
    },
    {
        "utterance": "Molly Bright: And mainly I'm a little distracted. Sorry guys. Um, the yeah, I I'd say that with my type of MRI, we um, we say we want metabolism, but what we typically are saying is we want neural activity. And that's such a different thing and yet we say it and and that's sort of a mindset issue. Um, the other thing is out of the prompts that we started with, the idea that metabolic changes proceed physiological changes, I think when we're looking at the brain and and we are using physiological measures of um, well what I would call physiological measures, we're using vascular properties to estimate a metabolic property. So the timeline of things is really important when we try to infer one from the other. So in the pathologies, knowing when we can trust our models of how vascular signals relate to metabolism or when those models have already broken down because metabolism wrecked that something about the vascular thing we're measuring. I'm not sure I'm being very coherent, but I feel like it's it's a big challenge that like with a lot of things with this neuro MRI view of metabolism, I feel like we're we're a bit superficial with it so far. ",
        "annotations": [
            {
                "explain or define term or concept": "Molly explains that in their type of MRI, they often say they want to measure metabolism, but they are actually measuring neural activity, highlighting a distinction between the two concepts."
            },
            {
                "expand on existing idea": "Molly expands on the initial prompt about metabolic changes preceding physiological changes, discussing the challenges of inferring metabolism from vascular properties in the brain and the importance of the timeline in pathologies."
            },
            {
                "express frustration": "Molly expresses frustration with the neuro MRI view of metabolism, feeling that it is currently superficial."
            }
        ]
    },
    {
        "utterance": "Molly Bright: Well metabolism, not MRS. I am not doing spectroscopy. ",
        "annotations": [
            {
                "explain or define term or concept": "Molly clarifies that she was referring to metabolism in general, not specifically MR spectroscopy, which is a specific technique."
            }
        ]
    },
    {
        "utterance": "Molly Bright: Just to put that out there. That's a very different thing and much more interpretable. ",
        "annotations": {
            "explain or define term or concept": "Molly is clarifying that her type of MRI is different from MRS (spectroscopy), which is more interpretable, to avoid confusion with Candace's earlier discussion of MRS."
        }
    },
    {
        "utterance": "Alex Walsh: Yeah, I think um, there's a lot of different things you can measure with metabolism, right? And uh, understanding the relationship between the molecules you're detecting and right your physiological outcome that you want to to actually know something about is is an important bridge that needs to be crossed. Um, so like when you do autofluorescence of NADH and FAD, we're very good at finding those molecules, but we're not so great at knowing what that tells us about metabolism. Um, and so I think that's that's the challenge for the field that I work in is trying to be more specific with things like metabolic pathways. ",
        "annotations": [
            {
                "expand on existing idea": "Building on the discussion about metabolic imaging and its applications, Alex expands on the idea by highlighting the importance of understanding the relationship between measured molecules and physiological outcomes, which was previously mentioned by Molly."
            },
            {
                "present new idea": "Alex introduces the idea that a key challenge in their field is to be more specific with things like metabolic pathways, which is a novel concept not previously mentioned."
            }
        ]
    },
    {
        "utterance": "Alex Walsh: So. ",
        "annotations": {
            "None": "This utterance does not contain any information that can be categorized by the codebook."
        }
    },
    {
        "utterance": "Matt Bogyo: Alex, can you expand on the limits of the using the endogenous fluorescence? ",
        "annotations": {
            "ask clarifying question": "Matt Bogyo is asking Alex to elaborate on the limitations of using endogenous fluorescence, which Alex mentioned in the previous turn."
        }
    },
    {
        "utterance": "Allison Dennis: So you know how how thick of a tissue can you look at? Is it only monoculture? Can you look at spheroid? Yeah, what what's the scope can you. ",
        "annotations": [
            {
                "ask clarifying question": "Allison is asking Alex to clarify the limitations of using endogenous fluorescence, specifically regarding the thickness of tissue that can be examined and whether it's limited to monocultures or if spheroids can be analyzed, building on Matt's question about the limits of using endogenous fluorescence."
            }
        ]
    },
    {
        "utterance": "Alex Walsh: Right. So it's it's just like normal fluorescence. So whatever techniques you use, it's it we can do it too. Um, so so we can do single photon and it's really great at looking at cells on a dish, but we can also adapt it for multiphoton and optical technologies that can do three-dimensional things like organoids or even in vivo up to a couple millimeters. ",
        "annotations": {
            "expand on existing idea": "Alex is expanding on the limits of using endogenous fluorescence, which Matt asked about in the previous turn.",
            "provide supporting evidence": "Alex provides supporting evidence by stating that they can use single photon techniques for cells on a dish and adapt multiphoton techniques for 3D structures like organoids or in vivo imaging up to a couple millimeters, supporting the idea that their techniques are versatile."
        }
    },
    {
        "utterance": "Matt Bogyo: I guess we should consider checking in with Kevin, seeing how uh how's things looking over there. Kevin, do we should probably pull together as a group and kind of summarize some of the main things we've been discussing so we have a sense of the report out. What do you think? ",
        "annotations": {
            "assign task": {
                "Explanation": "Matt Bogyo is assigning Kevin the task of summarizing the main points of the discussion for a report out."
            },
            "encourage particpatioin": {
                "Explanation": "Matt Bogyo is encouraging Kevin to participate by asking for his thoughts on summarizing the discussion."
            },
            "propose decision": {
                "Explanation": "Matt Bogyo is proposing the decision to check in with Kevin and summarize the discussion as a group."
            }
        }
    },
    {
        "utterance": "Kevin Cash: Yeah, it's it's currently quite chaotic. ",
        "annotations": {
            "express frustration": "Kevin expresses frustration with the current state of the notes, indicating that they are disorganized."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, it's a little bit all over. Do you have um some notes or do you want to share screen or do you how do you want to do it? ",
        "annotations": {
            "ask clarifying question": "Matt asks Kevin how he wants to summarize the discussion, inquiring about his notes or screen sharing preferences, after Kevin mentioned that the notes are chaotic.",
            "propose decision": "Matt suggests that the group should pull together and summarize the main points of the discussion, proposing a concrete action for the group."
        }
    },
    {
        "utterance": "Kevin Cash: Uh yeah, I can share the screen. ",
        "annotations": {
            "offer constructive criticism": "Kevin is responding to Matt's question about summarizing the discussion and offers to share his screen, which is a constructive way to proceed with the task."
        }
    },
    {
        "utterance": "Kevin Cash: So yeah, here's here's what I've got now that from the scattered notes that I've been taking throughout the the session. So I listed some of the targets that we talked about that were good proxies, some general comments on tying it together. ",
        "annotations": [
            {
                "explain or define term or concept": "Kevin is explaining what the shared document contains, which is a summary of targets and general comments discussed in the session."
            }
        ]
    },
    {
        "utterance": "Matt Bogyo: But I think some of the ",
        "annotations": [
            {
                "present new idea": "Matt is about to introduce a new idea or direction for the discussion, following the summary of the current state by Kevin."
            }
        ]
    },
    {
        "utterance": "Kevin Cash: The things that are worth bringing up like I don't know if it's worth bringing up the challenges of individual modalities to the the whole group when we come back, but some of the discussions about like, okay, amplifying the signal, that seems like a higher value addition to to bring up for discussion with the other groups of because that seems at least to me like a big challenge moving forward is how do we get these low concentration signals that might be more beneficial than just, okay, things like blood flow or things like oxygen. How can we get low concentration things that might be valuable to have a signal big enough to measure. ",
        "annotations": {
            "propose decision": {
                "Explanation": "Kevin suggests focusing on the discussion about amplifying the signal when reporting back to the larger group, as it represents a significant challenge in measuring low concentration signals."
            },
            "expand on existing idea": {
                "Explanation": "Kevin builds upon the previous discussion about challenges in metabolic imaging by highlighting the need to amplify low concentration signals to make them measurable and potentially more beneficial than current proxies like blood flow or oxygen."
            }
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, I like it. I mean, I think I think having one of our main bullet points or discussion points for the for the for the for the end would be, yeah, these challenges and limitations associated with imaging metabolites in particular. Um, I guess the question is to what I think it's good to break it down to like two or three or maybe four at most kind of main points and then um, pick from the sort of notes you have which look quite quite good. ",
        "annotations": [
            {
                "propose decision": "Matt suggests focusing the discussion on the challenges and limitations of imaging metabolites, building on the previous discussion about summarizing the main points for the report out."
            },
            {
                "expand on existing idea": "Matt expands on the idea of summarizing the discussion by suggesting to break it down to a few main points, building on Kevin's notes."
            }
        ]
    },
    {
        "utterance": "Matt Bogyo: Um what are people's thoughts? ",
        "annotations": {
            "encourage particpatioin": "Matt Bogyo is explicitly inviting others to share their opinions or perspectives on the discussion, continuing the conversation from the previous points."
        }
    },
    {
        "utterance": "Katharine White: Yeah, I agree with that and I think this idea of amplification is important for for low abundant metabolites or oncometabolites or disease associated metabolites that might be important diagnostically. But I do think that Allison, I think made a good point about under certain conditions you may want the ability to to look at this dynamically and to look at metabolite production dynamically over a longer cellular process. ",
        "annotations": [
            {
                "express agreement": "Katharine explicitly agrees with the points Matt and Kevin made about summarizing the main points of the discussion.",
                "expand on existing idea": "Katharine expands on the idea of amplification of signal for low abundant metabolites, adding that it is important for oncometabolites or disease associated metabolites that might be important diagnostically, building on the previous discussion about challenges and limitations associated with imaging metabolites.",
                "acknowledge contribution": "Katharine acknowledges Allison's point about the importance of looking at metabolite production dynamically over a longer cellular process, recognizing Allison's input."
            }
        ]
    },
    {
        "utterance": "Katharine White: Which also has as we've discussed a lot of a lot of potential challenges in terms of being able to do that quantitatively. ",
        "annotations": {
            "expand on existing idea": "This utterance builds upon the previously discussed challenges related to dynamically observing metabolite production, adding that doing so quantitatively also presents potential difficulties."
        }
    },
    {
        "utterance": "Ping Wang: I I do like a context uh comment on the data like integration because the complexity of the metabolic metabolics uh so process. So um, I I think we should have a one um, one um point uh for the um integrated um data like for the all the uh information from imaging and also uh if you're talking about clinical application other uh features in clinic um for the diagnosis purpose um using um AI or deep learning. Probably we don't have many deep learning people here, nobody mentioned that. ",
        "annotations": [
            {
                "present new idea": "Ping Wang introduces the idea of data integration using AI or deep learning for diagnosis, which hasn't been explicitly mentioned before in the discussion.",
                "propose decision": "Ping Wang suggests having a point for integrated data, including imaging and clinical features, for diagnostic purposes.",
                "encourage particpatioin": "Ping Wang notes that probably there are not many deep learning people here, implicitly inviting them to contribute to the discussion."
            }
        ]
    },
    {
        "utterance": "Lingyan Shi: And uh um I think we perhaps can add a bio marker into this uh tool for diagnostic uh purpose because uh for example the amyloid beta protein it has a very specific peak in Raman region, Raman bands. It is separable from other protein. So as long as there is amyloid beta then we can detect it with the specific peak only belong to this molecule. ",
        "annotations": {
            "present new idea": "The speaker introduces the idea of adding a biomarker to the diagnostic tool, which is a novel concept not previously discussed in this specific context.",
            "provide supporting evidence": "The speaker supports the idea of adding a biomarker by providing the example of amyloid beta protein, which has a specific peak in the Raman region, making it separable from other proteins, thus strengthening the idea of using biomarkers for diagnostic purposes.",
            "expand on existing idea": "The speaker expands on the existing idea of diagnostic tools by suggesting the addition of a biomarker and providing a specific example (amyloid beta protein) and its properties, building upon the discussion of diagnostic applications of metabolic imaging."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): how we balance, you know, different things for different applications. Um, and then talked about complexity of data interpretation, that's one challenges, one of the challenges. Uh, any other um, challenges that people want to mention? Do we want to, I guess Kevin, one one of Kevin's questions is whether we go through the the challenges for individual modality or talk about a few shared or or or common, right? Um, critical challenges for imaging metabolites. ",
        "annotations": {
            "expand on existing idea": "The speaker is building on the previous discussion about challenges and limitations associated with imaging metabolites, specifically how to balance different approaches for different applications.",
            "encourage particpatioin": "The speaker is inviting others to contribute by asking if there are any other challenges people want to mention, building on the previous discussion about challenges and limitations associated with imaging metabolites.",
            "propose decision": "The speaker is proposing a decision on whether to discuss challenges for individual modalities or shared challenges for imaging metabolites, following the discussion about challenges and limitations associated with imaging metabolites."
        }
    },
    {
        "utterance": "Allison Dennis, Boston U (she/her): think given the constraints of the the report out, keeping it to the general challenges, like there's always the challenge of signal to noise and the um, having enough signal for a small concentration analyte. Those things are endemic regardless of your modality. ",
        "annotations": {
            "expand on existing idea": "Allison is expanding on the idea of challenges in imaging metabolites, which was brought up by Jin and Kevin, by suggesting to focus on general challenges for the report out.",
            "provide supporting evidence": "Allison supports the idea of focusing on general challenges by mentioning the signal-to-noise ratio and having enough signal for a small concentration analyte as endemic issues regardless of modality."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Looks like we got about five minutes here, so you may want to start to consolidate and get this onto the slide deck maybe. ",
        "annotations": {
            "propose decision": "Matt suggests consolidating the discussion points and putting them on a slide deck, proposing a concrete action for the group to prepare for a report out."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: So what do you guys think is the most important other than the challenges? Like, do you think it's important to share with everyone some of the targets that we discussed? Do you think it's important to share some of these other questions we were talking about of heterogeneity or tying in genetics or focusing on talking about some other approaches? What do you guys think is most valuable for us to report back? ",
        "annotations": {
            "encourage particpatioin": "Kevin is asking for input from the group on what they think is most important to report back, encouraging them to share their thoughts.",
            "propose decision": "Kevin is suggesting different options for what to share with the larger group, such as targets, heterogeneity, genetics, or other approaches, and asking for a decision on which is most valuable."
        }
    },
    {
        "utterance": "Katharine White--Notre Dame: Um, I really liked, I think it was Candace's point about this um having a a genetic fingerprint or metabolomic fingerprint that that you could use diagnostically. Um, there's a lot of work that we need to do in order to, you know, identify the what what that fingerprint looks like um but I think that was a an interesting uh concept that from from our discussion that was exciting to me. ",
        "annotations": {
            "acknowledge contribution": "Katharine acknowledges Candace's point about genetic or metabolomic fingerprints, recognizing her input without necessarily agreeing or expanding on it.",
            "expand on existing idea": "Katharine expands on the idea of a genetic or metabolomic fingerprint for diagnostic use, mentioning the need to identify what that fingerprint looks like, building on Candace's earlier point.",
            "express enthusiasm": "Katharine expresses excitement about the concept of a genetic or metabolomic fingerprint for diagnostic use, indicating optimism and encouragement for this direction."
        }
    },
    {
        "utterance": "Lingyan Shi: ming establish a library for standard compounds that can be a target. ",
        "annotations": {
            "propose new idea": "Lingyan Shi proposes a new idea to establish a library for standard compounds that can be a target, which is a novel concept not previously mentioned in the discussion."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: I think we're going to have to make some decisions here. We got two minutes or three minutes. We're going to be the first ones reporting out. So I I think uh, you know, I don't know, personally, I I can give you my opinion. I think I think that um this giving some overview of the kinds of metabolites that are being reported on, talking about the modalities that we discussed and and then going into the limitations would probably be the most useful information for people, I would say. ",
        "annotations": {
            "propose decision": {
                "Explanation": "Matt proposes a concrete choice for the group regarding what to report out, given the limited time."
            }
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: What did you say for the first part? ",
        "annotations": {
            "ask clarifying question": "Kevin is asking Matt to repeat or clarify what he said about the first part of the summary, indicating he needs more information to understand or record it accurately."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Like talking about the types of um metabolites that are imaged. So you have a nice kind of list there of things that are, you know, what is sort of the cutting edge and what are people looking at and then um I think mentioning the modalities that are used and then the limitations. I think that that was kind of the bulk of a lot of our discussion. ",
        "annotations": {
            "propose decision": {
                "Explanation": "Matt proposes a structure for the report-out, suggesting to talk about the types of metabolites imaged, the modalities used, and the limitations, building on the previous discussion about what to include in the report."
            }
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, that sounds great. ",
        "annotations": {
            "express agreement": "The speaker explicitly agrees with the suggestion made by Matt Bogyo to summarize the discussion points, indicating agreement with the proposed plan."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): So the the first uh bullet point. ",
        "annotations": {
            "propose decision": "Jin Zhang is suggesting to focus on the first bullet point, which is a concrete choice for the group to discuss."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Yeah, I know. ",
        "annotations": {
            "express agreement": "Matt Bogyo is agreeing with Jin Zhang's previous statement about the first bullet point."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah. ",
        "annotations": [
            {
                "express agreement": "The speaker explicitly agrees with the suggestion made in the previous utterance."
            }
        ]
    },
    {
        "utterance": "Jin Zhang (UCSD): and the limitations, right? And the modalities in the need. ",
        "annotations": [
            {
                "confirm decision": "This utterance confirms Matt's suggestion to focus on the types of metabolites imaged, the modalities used, and the limitations, solidifying the group's decision on what to report back."
            }
        ]
    },
    {
        "utterance": "Lingyan Shi: I think I have a comments on the the and problem is a question driven or tech technical driven, maybe biological question driven will give us a very clear target molecule, so we can seek the tool easier. Find out which one is the best. ",
        "annotations": {
            "present new idea": "Lingyan suggests that focusing on biological questions rather than technical aspects will lead to clearer target molecules, which will make it easier to find the right tools, introducing a novel approach to target identification.",
            "expand on existing idea": "Lingyan expands on the discussion about challenges in imaging metabolites by suggesting a question-driven approach to identify target molecules, building upon the previous discussion about limitations and challenges.",
            "propose decision": "Lingyan proposes that a biological question-driven approach should be used to identify target molecules, suggesting a concrete choice for the group to consider.",
            "express agreement": "Lingyan agrees with the previous discussion about the challenges and limitations of imaging metabolites and proposes a solution to address these challenges."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, definitely uh we we kind of covered that sort of application based uh considerations, right? ",
        "annotations": {
            "express agreement": "The speaker agrees with the previous statement about application-based considerations, indicating alignment with the discussion."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Great. Great discussions. Thanks everyone. ",
        "annotations": {
            "express agreement": "The speaker expresses agreement with the discussions that have taken place."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Thanks Matt. ",
        "annotations": {
            "acknowledge contribution": "Jin Zhang acknowledges Matt's contribution to the discussion, showing appreciation for his input."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Yep, thank you. Jen, we'll see you guys in the main room. ",
        "annotations": [
            {
                "acknowledge contribution": "Matt Bogyo acknowledges the contributions of the participants in the discussion."
            }
        ]
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah. ",
        "annotations": {
            "express agreement": "The speaker expresses agreement with the previous statement."
        }
    },
    {
        "utterance": "Lingyan Shi: Thank you. ",
        "annotations": [
            {
                "acknowledge contribution": "Lingyan Shi is acknowledging the discussion by saying thank you."
            }
        ]
    },
    {
        "utterance": "Lingyan Shi: Bye. ",
        "annotations": [
            {
                "None": "This utterance does not fit into any of the codes provided."
            }
        ]
    },
    {
        "utterance": "Lingyan Shi: Thank you, Kevin. ",
        "annotations": {
            "acknowledge contribution": "Lingyan Shi acknowledges Kevin's contribution as the reporter for the group."
        }
    },
    {
        "utterance": "Silvia Ronco, RCSA:  ",
        "annotations": {
            "None": "There is no relevant code to apply to this utterance."
        }
    },
    {
        "utterance": "Aniruddha Ray:  ",
        "annotations": {
            "None": "This utterance does not contain any content and does not fit any of the defined codes."
        }
    }
]